Mabwell Biotech

Executive Summary

Mabwell Biotech is a Shanghai-based integrated biopharmaceutical company focused on developing innovative monoclonal antibodies and biologics for oncology and autoimmune diseases. Founded in 2017, the company has built a comprehensive platform spanning antibody discovery, clinical development, and commercial manufacturing. With over 500 employees and a public listing, Mabwell has advanced several candidates into clinical trials, most notably its Nectin-4-directed antibody-drug conjugate (ADC) 9MW2821, which is in Phase 2/3 for multiple solid tumors including urothelial and breast cancers. In autoimmune disease, the company’s IL-17A/F bispecific antibody 9MW1911 is progressing in Phase 2 for psoriasis and ankylosing spondylitis. Mabwell’s strategy emphasizes first-in-class and best-in-class biologics targeting high unmet medical needs in China and globally, leveraging its proprietary platforms to accelerate development. Despite competitive pressures, the company’s robust pipeline and manufacturing capabilities position it as a notable player in China’s biotech landscape.

Upcoming Catalysts (preview)

• Q3 20269MW2821 Phase 2 data readout in urothelial carcinoma65% success
• Q4 20269MW1911 Phase 2 topline results in moderate-to-severe psoriasis60% success
• TBDPotential licensing or partnership deal for 9MW2821 outside China40% success